Haemonetics (HAE) Tops Q4 EPS by 1c, Offers Guidance
Tweet
Share
E-mailGet Alerts HAE Hot Sheet
Price: $101.06 -2.04%
Revenue Growth %: +5.5%
Financial Fact:
Research, development and engineering: 8.34M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +5.5%
Financial Fact:
Research, development and engineering: 8.34M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Haemonetics (NYSE: HAE) reported Q4 EPS of $0.43, $0.01 better than the analyst estimate of $0.42. Revenue for the quarter came in at $233.6 million versus the consensus estimate of $227.12 million.
GUIDANCE:
Haemonetics sees FY2019 EPS of $2.00-$2.30, versus the consensus of $2.09.
For earnings history and earnings-related data on Haemonetics (HAE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
- Core & Main, Inc (CNM) Tops Q3 EPS by 2c ; Offers Guidance
- AeroVironment (AVAV) Tops Q1 EPS by 29c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
